Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases - Wikidata - awgldk - TriplyDB

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

http://www.wikidata.org/entity/Q28076496

about

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Advances in targeted therapy.New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis

P2860

Q38661046-D1354E28-581A-4161-843F-FEF062E382E3 Q39458219-E3512AF6-3BBC-48EB-A810-C65531108D49 Q48296840-3805196D-A397-49A5-9233-5923B91B6A74 Q53695267-CB59B4FB-BF8B-4CCB-BEF5-B825385732F9 Q53707988-76FB0737-D43D-4981-8D2C-577C6A59ABF9 Q58803309-0A383B08-CF1E-46A3-97EF-BB9E996B9D74

P2860

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

http://www.wikidata.org/entity/Q28076496

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@ast

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@en

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@nl

type

label

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@ast

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@en

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@nl

prefLabel

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@ast

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@en

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@nl

P1433

Q28076496-D5D393EF-0183-4347-97DA-6F782ED4DA31

P1476

Q28076496-7C48E11F-945B-4F63-AA25-A3823E01C4EA

P2093

Q28076496-3169238D-908C-424D-B73E-C6EDC712F805

Q28076496-46A76177-F48B-4445-BD1E-D317F91A2EDC

Q28076496-6EA6F936-A947-4426-8E84-B1C110853E93

Q28076496-8CAFC692-4947-4CCC-A098-FA88FF3C4826

Q28076496-C84959C6-F50B-4B4E-8CF3-102D05F2144D

Q28076496-D2193C95-78D0-416D-AD3F-6A26398842E4

Q28076496-DDA24B5A-2DB4-4F5D-B6CD-8AFC60509715

Q28076496-FA04FE3C-ABEF-41FA-9FFC-B31A2B46A083

P2860

Q28076496-02270659-9686-4F33-B97E-585BF7B8DAFF

Q28076496-058D9B46-B658-488F-B509-F0E835C5BEF1

Q28076496-0730D6ED-62AB-453A-9A4C-FE62B1780DCD

Q28076496-084799B8-7CA0-41F8-A7CA-2BAC327F459D

Q28076496-0E1F5189-697D-4CB6-AB9E-B6C1464FA8DF

Q28076496-144692A7-8164-4F0D-B771-39C2A50A1020

Q28076496-183B57FE-FB1E-460C-9414-F3A61B313F49

Q28076496-1AADCFB7-C0EE-4A63-ADDA-81BC68883E8F

Q28076496-1DBCD9E5-D3C4-4377-B5A1-88C77A382927

Q28076496-206EDEDD-C00E-421A-984A-222FBD8A9BB8

P304

Q28076496-43D02F90-34C4-4B3B-9E0E-EC19ED03925E

P31

Q28076496-F9D96CC9-CA56-4D76-A099-5AA0533B2DEE

P356

Q28076496-CB8E4DEB-78A2-4C25-9618-35937E255AC7

P407

Q28076496-CB0AB467-7DFE-40FB-A15E-7425831A1BC5

P433

Q28076496-48B6B362-8979-4CF9-9F23-EA637D6643AB

P478

Q28076496-7AF92C2C-57DD-4D2A-90AC-8FEBB2662BEB

P50

Q28076496-F97BC30C-1C36-4382-A488-7B7D8D2390AF

P577

Q28076496-8DF4CC3F-7F86-4D96-A84F-A5B57F63FA42

P698

Q28076496-D1A85864-74D6-49AE-A602-A22D9B94BDA6

P356

P1433

P1476

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

@en

P2093

Ajay Nirula

http://www.w3.org/2001/XMLSchema#string

Alison L Budelsky

http://www.w3.org/2001/XMLSchema#string

David A Martin

http://www.w3.org/2001/XMLSchema#string

Greg Kricorian

http://www.w3.org/2001/XMLSchema#string

Jennifer E Towne

http://www.w3.org/2001/XMLSchema#string

Jon Nilsen

http://www.w3.org/2001/XMLSchema#string

Ngozi Erondu

http://www.w3.org/2001/XMLSchema#string

Paul Klekotka

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

IL-17C regulates the innate immune function of epithelial cells in an autocrine manner

Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F

Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease

Structure and signalling in the IL-17 receptor family

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways

Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract

P304

ii43-ii55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEW346

http://www.w3.org/2001/XMLSchema#string

P407

P433

suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27856660

http://www.w3.org/2001/XMLSchema#string